Document is current
Any future updates will be listed below
-
Authors
Raj Murthi, Sarala
Petry, Andreas
Shashikadze, Bachuki
Stöckl, Jan B.
Schmid, Manuel
Santamaria, Gianluca
Klingel, Karin
Kračun, Damir
Chen, Xinpei
Bauer, Sabine
Schmitt, Joachim P.
Flenkenthaler, Florian
Gorham, Josh
Toepfer, Christopher N.
Potěšil, David
Hruška, Pavel
Zdráhal, Zbyněk
Mayer, Zsuzsanna
Klop, Mathieu
Lehmann, Luisa
Qin, Yishi
Papanakli, Laura
Spielmann, Nadine
Moretti, Alessandra
Fröhlich, Thomas
Ewert, Peter
Holdenrieder, Stefan
Seidman, Jonathan G.
Seidman, Christine E.
Görlach, Agnes
Wolf, Cordula M.
-
Funding
Funding for this research was provided by:
Technische Universität München
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 1 January 2025
First Online: 16 January 2025
Declarations
:
: Wolf CM: Honoraria: Novo Nordisk and Bristol-Myers Squibb; Dr. Wolf is a consultant for Day One Biopharmaceuticals, Inc., BioMarin Pharmaceuticals, Adrenomed AG, and Pliant Therapeutics. Dr. Wolf has ownership interest (Preventage Therapeutics). There are no other competing financial and non-financial interests
